Journal of Translational Medicine

Table 2 Combination indexes assessing synergism/additivity/antagonism in rapamycin and LY294002

From: Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer

LY294002	Rapamycin	A498	ACHN	CAKI-1	CAKI-2	769-P	786-O
(nM)	(nM)	(CI)	(CI)	(CI)	(CI)	(CI)	(CI)
5000	500	0.476	0.371	0.593	0.201	0.430	0.242
5000	100	0.461	0.193	0.492	0.212	0.444	0.262
5000	20	0.441	0.173	0.472	0.184	0.385	0.281
25000	500	1.388	0.678	1.409	1.270	1.356	0.830
25000	100	1.420	0.586	1.193	1.074	1.430	0.847
25000	20	1.393	0.484	1.227	1.020	1.530	0.910

Synergism is indicated by a CI of < 0.9, additivity by CI values between 0.9 and 1.1, and antagonism by CI of > 1.1.

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com